Verition Fund Management
KZR

Verition Fund Management’s Kezar Life Sciences KZR Stock Holding History

Verition Fund Management’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,190
Closed -$7.14K – 3372
2024
Q2 		$7.14K Buy
+1,190
New +$9.04K ﹤0.01% 2900
2023
Q3 		– Sell
-3,956
Closed -$96.9K – 2517
2023
Q2 		$96.9K Sell
3,956
-2,951
-43% -$76.8K ﹤0.01% 1982
2023
Q1 		$216K Buy
+6,907
New +$400K ﹤0.01% 1723

Other funds holding KZR

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Verition Fund Management's KZR Position: Q3 2024 in Review

Verition Fund Management sold out of Kezar Life Sciences (KZR) in Q3 2024, closing a stake of 1,190 shares — an estimated $7.14K sold.

Verition Fund Management first reported a position in KZR in Q1 2023 and held it in 3 quarters. The position peaked at $216K in Q1 2023. 59 funds tracked by Wall St. Rank hold KZR as of Q3 2024.

  • Verition Fund Management reported no remaining Kezar Life Sciences position as of Q3 2024 after selling out during the quarter.
  • Verition Fund Management sold 1,190 Kezar Life Sciences shares in Q3 2024, an estimated $7.14K.
  • Verition Fund Management first reported a position in Kezar Life Sciences in Q1 2023 and held it in 3 quarters.
  • Verition Fund Management's Kezar Life Sciences position peaked at $216K in Q1 2023.
  • 59 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q3 2024.

Based on Verition Fund Management's 13F filing for Q3 2024, filed 14 Nov 2024.